Published finding — does the expert body still believe it?
The CheckMate-067 trial's stated primary conclusion — Nivolumab + ipilimumab combination yields superior long-term survival in advanced melanoma vs. either monotherapy. — replicates in independent cohorts.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al. · New England Journal of Medicine · 2017
· openalex W2753432434
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1240
In previously untreated metastatic melanoma patients with PD-L1-negative tumors, nivolumab plus ipilimumab produces longer progression-free survival (11.2 months) than nivolumab monotherapy (5.3 months).
0.1264
In previously untreated metastatic melanoma patients with PD-L1-positive tumors, nivolumab monotherapy achieves equivalent median progression-free survival (14.0 months) to nivolumab plus ipilimumab combination therapy.
0.1270
In previously untreated patients with unresectable stage III/IV melanoma, nivolumab plus ipilimumab achieves a median progression-free survival of 11.5 months versus 2.9 months with ipilimumab alone (HR 0.42, P<0.001).
0.1344
Recent follow-up analyses of CheckMate-067 are confirming the original effect size in real-world data.
0.1361
Pembrolizumab's PFS and OS benefit over ipilimumab in advanced melanoma will be maintained at longer follow-up beyond the median 7.9-month observation period reported in this trial.
0.1407
Pembrolizumab (10 mg/kg every 2 weeks) improves 12-month overall survival to 74.1% versus 58.2% for ipilimumab (HR 0.63, P=0.0005) in patients with advanced melanoma.